In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Utility Before Profitability: The Evolving Evidence Paradigm For Molecular Diagnostics

Executive Summary

The standards needed for reimbursement of molecular diagnostics are changing – especially with respect to genomics-based tests, with their potential impact on public health with respect to screening, prevention, and measuring response to treatment, as well as cost. As the complexity of the assay development and launch process has grown, so too has the emphasis on evidence and clinical effectiveness, as well as the importance of finding better ways to align test coding and reimbursement with clinical value. But a lack of coordination across agencies and commercial players makes an assessment of the impact of any changes on evidence demands problematic.


Related Content

Multi-Gene Expression Test Helps Rule Out Thyroid Surgery In Large Study
FDA Companion, Co-Development Dx Guidances On Track, Official Says
Genomics Through The Lens Of Precompetitive Data Sharing
Veracyte Meets New Medicare Coverage Mandate For Molecular Dx
Views Differ On How Lab-Developed Tests Fit In FDA Companion Dx Guidance
Molecular Dx Reimbursement: Medicare Contractor Seeks Tighter Controls
What's Fueling The Recent Diagnostics Dealmaking?
The How And When Of Applying Sequencing To Clinical Diagnostics
Quest, Vermillion Begin U.S. Marketing Push For Ovarian Cancer Test
LabCorp Pulls OvaSure, But Charges FDA With Overreaching


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts